Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Venezuela receives doses of Russian EpiVacCorona vaccine for trials

Published 03/30/2021, 03:03 PM
Updated 03/30/2021, 03:05 PM
© Reuters. FILE PHOTO: A Venezuelan health worker prepares to vaccinate a colleague with Russia's Sputnik V vaccine against the coronavirus disease (COVID-19), at a hospital, in Caracas

© Reuters. FILE PHOTO: A Venezuelan health worker prepares to vaccinate a colleague with Russia's Sputnik V vaccine against the coronavirus disease (COVID-19), at a hospital, in Caracas

CARACAS (Reuters) - Russia has supplied Venezuela with doses of EpiVacCorona to be used as part of trials of the Russian coronavirus vaccine candidate, officials said on Tuesday.

Russia has said that more than 115,000 EpiVacCorona doses have been deployed in its national inoculation program, calling it "100% effective" in producing antibodies - though some trial volunteers have expressed concerns about its efficacy.

Venezuelan President Nicolas Maduro has said his government will receive 10 million doses of the Sputnik V COVID-19 vaccine, Russia's flagship inoculation, but so far has received only several hundred thousand doses.

"We provided 1,000 doses of the vaccine EpiVacCorona, which is a vaccine that has shown positive results," Russia's deputy prime minister, Yuri Borisov, said, via an interpreter, during a visit to Venezuela. "We could consider supplying that vaccine in addition to Sputnik V."

Venezuelan Science Minister Gabriela Jimenez earlier in the day tweeted that EpiVacCorona doses had arrived as part of trials that would take place in Venezuela.

The South American nation has received about 500,000 doses of the coronavirus vaccine manufactured by China's Sinopharm and about 250,000 from the Russian Sputnik V.

Venezuela, along with allies of opposition leader Juan Guaido, is in talks to buy vaccines from the COVAX program using funds frozen in the United States.

COVAX, the World Health Organization's program designed to secure COVID-19 vaccines for poor countries, has set aside up to 2.4 million doses of the AstraZeneca (NASDAQ:AZN) vaccine, pending a payment agreement.

© Reuters. FILE PHOTO: A Venezuelan health worker prepares to vaccinate a colleague with Russia's Sputnik V vaccine against the coronavirus disease (COVID-19), at a hospital, in Caracas

But Maduro has said Venezuela will not accept AstraZeneca doses following concerns about side effects. The World Health Organization this month said the benefits of AstraZeneca's vaccine outweighed the risks.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.